These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36992377)

  • 1. Research Advances on the Stability of mRNA Vaccines.
    Cheng F; Wang Y; Bai Y; Liang Z; Mao Q; Liu D; Wu X; Xu M
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case.
    Oude Blenke E; Örnskov E; Schöneich C; Nilsson GA; Volkin DB; Mastrobattista E; Almarsson Ö; Crommelin DJA
    J Pharm Sci; 2023 Feb; 112(2):386-403. PubMed ID: 36351479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in mRNA vaccines.
    Li M; Wang Z; Xie C; Xia X
    Int Rev Cell Mol Biol; 2022; 372():295-316. PubMed ID: 36064266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Biopharmaceutical Perspective on Higher-Order Structure and Thermal Stability of mRNA Vaccines.
    Kloczewiak M; Banks JM; Jin L; Brader ML
    Mol Pharm; 2022 Jul; 19(7):2022-2031. PubMed ID: 35715255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles for designing an optimal mRNA lipid nanoparticle vaccine.
    Kon E; Elia U; Peer D
    Curr Opin Biotechnol; 2022 Feb; 73():329-336. PubMed ID: 34715546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy.
    Kim HJ; Seo SK; Park HY
    J Control Release; 2022 May; 345():405-416. PubMed ID: 35314261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine.
    Muramatsu H; Lam K; Bajusz C; Laczkó D; Karikó K; Schreiner P; Martin A; Lutwyche P; Heyes J; Pardi N
    Mol Ther; 2022 May; 30(5):1941-1951. PubMed ID: 35131437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Size and Charge Characterization of Lipid Nanoparticles for mRNA Vaccines.
    Malburet C; Leclercq L; Cotte JF; Thiebaud J; Bazin E; Garinot M; Cottet H
    Anal Chem; 2022 Mar; 94(11):4677-4685. PubMed ID: 35254048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies.
    Li H; Peng K; Yang K; Ma W; Qi S; Yu X; He J; Lin X; Yu G
    Theranostics; 2022; 12(14):6422-6436. PubMed ID: 36168634
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R848 Adjuvant Laden With Self-Assembled Nanoparticle-Based mRNA Vaccine Elicits Protective Immunity Against H5N1 in Mice.
    Zhuang X; Chen L; Yang S; Xia S; Xu Z; Zhang T; Zeng B; Yu T; Yu N; Wang W; Lu H; Tian M; Jin N
    Front Immunol; 2022; 13():836274. PubMed ID: 35711431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced nanoscale delivery systems for mRNA-based vaccines.
    Mobasher M; Ansari R; Castejon AM; Barar J; Omidi Y
    Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130558. PubMed ID: 38185238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery Strategies for mRNA Vaccines.
    Ramachandran S; Satapathy SR; Dutta T
    Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates.
    Ripoll M; Bernard MC; Vaure C; Bazin E; Commandeur S; Perkov V; Lemdani K; Nicolaï MC; Bonifassi P; Kichler A; Frisch B; Haensler J
    Biomaterials; 2022 Jul; 286():121570. PubMed ID: 35576809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence-Optimized mRNA Vaccines Against Infectious Disease.
    Rauch S; Lutz J; Mühe J; Kowalczyk A; Schlake T; Heidenreich R
    Methods Mol Biol; 2024; 2786():183-203. PubMed ID: 38814395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and applications of mRNA treatment based on lipid nanoparticles.
    Wang Z; Ma W; Fu X; Qi Y; Zhao Y; Zhang S
    Biotechnol Adv; 2023; 65():108130. PubMed ID: 36933868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mRNA extraction from lipid nanoparticles.
    Malburet C; Carboni A; Guinamand S; Naik H; Fertier-Prizzon S
    J Chromatogr A; 2024 Jan; 1714():464545. PubMed ID: 38070303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV
    Valentin A; Bergamaschi C; Rosati M; Angel M; Burns R; Agarwal M; Gergen J; Petsch B; Oostvogels L; Loeliger E; Chew KW; Deeks SG; Mullins JI; Pavlakis GN; Felber BK
    Front Immunol; 2022; 13():945706. PubMed ID: 35935984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects.
    Huang T; Peng L; Han Y; Wang D; He X; Wang J; Ou C
    Front Immunol; 2022; 13():922301. PubMed ID: 36090974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.